Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Loses Pravachol Exclusivity Period; Multiple Generics To Launch In 2006

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA tells Teva that the 180-day exclusivity period for three pravastatin doses expired in February. As a result, as many as six companies – including Teva – could be in a position to launch generic Pravachol when Bristol’s composition of matter patent expires in April 2006. Teva plans to sue FDA to reinstate its first-to-file exclusivity period.

You may also be interested in...



Teva’s Generic Pravachol Will Be Approved – With Exclusivity, FDA Decrees

FDA has determined that a court dismissal does not constitute a decision under the “court decision trigger” provision, although the agency’s stance must be affirmed by the D.C. district court.

Teva’s Generic Pravachol Will Be Approved – With Exclusivity, FDA Decrees

FDA has determined that a court dismissal does not constitute a decision under the “court decision trigger” provision, although the agency’s stance must be affirmed by the D.C. district court.

Pravachol Exclusivity Case Remanded To FDA By Appeals Court

FDA needs to develop policy to determine whether a voluntary patent case dismissal triggers exclusivity, the court said.

Related Content

Topics

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel